Public Health Today—May 29, 2026

LucidQuest

4 hours ago

This week’s public health update covers advances in cardiovascular and neurodegenerative research, evolving screening and diagnostic guidance, vaccine and outbreak preparedness initiatives, and growing scrutiny of digital healthcare delivery models.

In Today’s Newsletter

Dive deeper

💊 VERVE-102 shows durable LDL-C lowering in Phase 1b [1] [US • 29 May 2026]

https://www.prnewswire.com/news-releases/a-single-dose-of-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-by-up-to-88-and-ldl-c-by-up-to-62-with-durable-effects-supporting-its-potential-as-a-one-time-treatment-for-hypercholesterolemia-302780172.html
Context: Trial enrolled 35 adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. Effects were reported as durable up to 18 months, with no serious adverse events or dose-limiting toxicities.
Key point: VERVE-102 (Eli Lilly; Verve Therapeutics, PCSK9 base editor) reduced PCSK9 by up to 88% and LDL-C by up to 62% after a single infusion in the Phase 1b Heart-2 study.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 UCSF blood biomarker study links Alzheimer’s markers to cognitive decline [2] [US • 29 May 2026]

https://www.sfgate.com/bayarea/article/ucsf-alzheimers-disease-cognitive-22279169.php
Context: Analysis included 1,350 CARDIA participants (average age 61). Biomarkers included tau and amyloid-related measures from blood tests.
Key point: University of California, San Francisco researchers reported that middle-aged adults with Alzheimer’s-related blood biomarkers were more likely to experience faster cognitive decline over time.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚖️ Online GLP-1 prescribing raises safety and overdose concerns [3] [US • 29 May 2026]

https://www.nbcnews.com/health/health-news/glp1-weight-loss-drugs-online-safety-risks-overdose-rcna347187
Context: Report cites increased poison-control calls and medication-error reports, including concerns around compounded formulations and limited clinical monitoring.
Key point: Expanding telehealth access to GLP-1 drugs such as semaglutide is associated with rising reports of dosing errors, overdoses, and inconsistent patient screening.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🌍 Rural health researchers propose target trial emulation for evidence generation [4] [29 May 2026]

https://medicalxpress.com/news/2026-05-rural-health-bypass-rct-hurdles.html
Context: Authors cited barriers including small populations, workforce shortages, and limited infrastructure in remote healthcare systems.
Key point: Griffith University researchers proposed “target trial emulation” using real-world data as an alternative to conventional randomized controlled trials in rural settings.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💉 WHO members reaffirm Immunization Agenda 2030 commitments [5] [Global • 26 May 2026]

https://www.who.int/news/item/26-05-2026-global-health-leaders-reaffirm-commitment-to-immunization-agenda-2030
Context: Delegates highlighted rising measles outbreaks, declining routine vaccination coverage, and widening inequities among zero-dose populations.
Key point: WHO and more than 70 Member States reaffirmed support for Immunization Agenda 2030 during the Seventy-ninth World Health Assembly.
Implication: May expand screening, initiation, and follow-up at scale.

🦠 WHO prioritizes Bundibugyo Ebola candidates for trials [6] [DRC–Uganda • 28 May 2026]

https://www.who.int/news/item/28-05-2026-experts-convened-by-who-advise-on-candidate-treatments-and-vaccines-for-ebola-disease-caused-by-bundibugyo-virus
Context: Prioritized therapies included MBP134, Maftivimab®, remdesivir, and combination regimens. Vaccine candidates included rVSV Bundibugyo (IAVI) and ChAdOx1 Bundibugyo (Oxford/Serum Institute).
Key point: WHO advisory groups prioritized candidate therapies and vaccines for Ebola disease caused by Bundibugyo virus, recommending use within controlled clinical trials only.
Implication: Signals pipeline investment and modality expansion.

🩺 ACS expands colorectal cancer screening options [7] [US • 29 May 2026]

https://pressroom.cancer.org/colorectal-cancer-screening-guideline-update-2026
Context: Guidance continues to recommend screening from ages 45–75 for average-risk adults, with colonoscopy remaining the reference standard.
Key point: American Cancer Society updated colorectal cancer screening guidelines to include additional blood-based and at-home stool testing options.
Implication: May expand screening, initiation, and follow-up at scale.

🦟 Study suggests mosquitoes can learn attraction to Deet [8] [29 May 2026]

https://www.theguardian.com/environment/2026/may/28/deet-mosquito-spray-attract-insects-study-malaria-zika
Context: Conditioned mosquitoes later showed greater attraction to Deet-treated surfaces compared with controls.
Key point: Journal of Experimental Biology research suggests mosquitoes can associate Deet exposure with blood feeding under laboratory conditions.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧬 Estrogen-linked extracellular matrix changes may contribute to Alzheimer’s risk [9] [29 May 2026]

https://neurosciencenews.com/estrogen-loss-extracellular-matrix-alzheimers-30762/
Context: Study focused on aromatase-driven estrogen production and its role in maintaining hippocampal support structures.
Key point: Northwestern researchers linked post-menopausal estrogen loss to structural breakdown of the hippocampal extracellular matrix in mouse models.
Implication: Signals pipeline investment and modality expansion.

🍔 French cohort study links food preservatives with hypertension risk [10] [EU • 29 May 2026]

https://scitechdaily.com/study-warns-widely-used-food-preservatives-linked-to-high-blood-pressure-and-heart-disease/
Context: Observational analysis included 112,395 adults followed for approximately seven to eight years.
Key point: NutriNet-Santé investigators reported associations between higher intake of several food preservatives and increased hypertension and cardiovascular disease risk.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Gene-editing programs such as VERVE-102 continue shifting cardiovascular treatment strategies toward one-time interventions rather than chronic maintenance therapy.
Blood-based diagnostics for Alzheimer’s disease are advancing faster than consensus around interpretation, screening thresholds, and clinical implementation.
GLP-1 demand is reshaping telehealth prescribing models, increasing pressure for clearer regulatory and safety standards.
WHO vaccine and Ebola discussions highlight continued emphasis on outbreak preparedness, manufacturing resilience, and equitable access.
Expanded colorectal cancer screening options may improve adherence among underserved populations reluctant to undergo colonoscopy.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Public Health archive on our research hub page.

FAQ

What is VERVE-102 and why is it notable? [1]

VERVE-102 is an investigational in vivo PCSK9 base-editing therapy from Eli Lilly and Verve Therapeutics. It is designed to permanently disable the PCSK9 gene in the liver after a single infusion. Early Heart-2 data showed durable LDL-C reductions, with follow-up reported up to 18 months. [1]

What did the UCSF Alzheimer’s biomarker study show? [2]

Researchers found that middle-aged adults with elevated blood biomarkers linked to amyloid and tau pathology were more likely to experience accelerated cognitive decline during follow-up. Participants did not have diagnosed Alzheimer’s disease at enrollment. [2]

Why are regulators concerned about online GLP-1 prescribing? [3]

Reports describe increasing medication errors, overdoses, and use of compounded GLP-1 products through telehealth channels. Concerns include limited patient evaluation, unclear dosing instructions, and fragmented oversight standards. [3]

What changed in the American Cancer Society colorectal screening guideline? [7]

The ACS added blood-based screening tests and newer stool-based options such as ColoSense alongside existing FIT, gFOBT, and colonoscopy approaches. Blood tests are recommended primarily for people declining other screening methods. [7]

Which Bundibugyo Ebola candidates did WHO prioritize? [6]

WHO advisory groups identified MBP134, Maftivimab®, remdesivir, and selected vaccine candidates including rVSV Bundibugyo and ChAdOx1 Bundibugyo for evaluation in clinical trials during the current outbreak response. [6]

Does the Deet mosquito study mean repellents no longer work? [8]

No. Researchers and outside experts emphasized that Deet remains effective in real-world use. The conditioning effects were observed under laboratory conditions and may not reflect normal repellent application patterns. [8]

Entities / Keywords

VERVE-102, PCSK9, LDL-C, Eli Lilly, Verve Therapeutics, Heart-2
UCSF, CARDIA, Alzheimer’s disease, tau, amyloid biomarkers
GLP-1, semaglutide, telehealth prescribing, compounded drugs
Target trial emulation, real-world evidence, rural health
WHO, Immunization Agenda 2030, measles, vaccine equity
Bundibugyo virus, Ebola, MBP134, remdesivir, rVSV Bundibugyo
American Cancer Society, colorectal cancer screening, ColoSense, Cologuard
Deet, mosquito behavior, malaria, dengue
Estrogen loss, extracellular matrix, hippocampus, aromatase
NutriNet-Santé, food preservatives, hypertension, cardiovascular disease